RELMADA THERAPEUTICS, INC.
For the period ended May 27, 2026. Filed Apr 17, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 27, 2026 · Filed Apr 17, 2026
Use the contents to explore the available documents and sections.
Contents
Additional Information
Accompanying this Proxy Statement is a copy of our Annual Report for the year ended December 31, 2025. Such report constitutes our Annual Report to Stockholders for purposes of Rule 14a-3 under the Exchange Act. Such report includes our audited financial statements for the fiscal year ended December 31, 2025 and certain other financial information, which is incorporated by reference herein. We are subject to the informational requirements of the Exchange Act and in accordance therewith file reports, proxy statements and other information with the SEC. Such reports, proxy statements and other information are available on the SEC’s website atwww.sec.gov.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.